Application Note
Quantifying changes in CD28 and CTLA-4 levels in peripheral blood mononuclear cells with AlphaLISA technology
One approach to immunotherapy is the modulation of immune checkpoints that are critical in regulating the degree and duration of immune system responses and preventing autoimmunity.
In this application note, you will learn:
- Why AlphaLISA™ technology is a useful assay for the detection and quantification of biomarkers such as CD28 and CTLA-4
- How to run an AlphaLISA assay to detect and quantify immuno-oncology biomarkers
- Benefits of using Alpha technology for biomarker quantification assays
- An example of the data and analysis you can generate for biomarker assays
For research use only. Not for use in diagnostic procedures.
Download Resource
Quantifying changes in CD28 and CTLA-4 levels in peripheral blood mononuclear cells with AlphaLISA technology